Resverlogix (TSE:RVX) Issues Quarterly Earnings Results

Resverlogix (TSE:RVX) posted its earnings results on Friday. The biotechnology company reported C$0.01 earnings per share for the quarter, FiscalAI reports.

Resverlogix Price Performance

RVX stock opened at C$0.10 on Friday. The business has a 50 day moving average price of C$0.11 and a 200 day moving average price of C$0.10. The stock has a market cap of C$30.04 million, a price-to-earnings ratio of -3.17 and a beta of 0.72. Resverlogix has a fifty-two week low of C$0.04 and a fifty-two week high of C$0.30. The company has a quick ratio of 0.04, a current ratio of 0.04 and a debt-to-equity ratio of -81.94.

About Resverlogix

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.